Research programme: atherosclerosis therapeutics - KineMed/Merck
Latest Information Update: 24 Aug 2011
At a glance
- Originator KineMed; Merck AG
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Atherosclerosis
Most Recent Events
- 24 Aug 2011 No development reported - Preclinical for Atherosclerosis in USA (unspecified route)